The United Laboratories International Holdings Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ULIHF research report →
Companywww.tul.com.cn
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products.
- CEO
- Hoi Shan Tsoi
- IPO
- 2014
- Employees
- 17,000
- HQ
- Yuen Long, HK
Price Chart
Valuation
- Market Cap
- $2.53B
- P/E
- 7.19
- P/S
- 1.15
- P/B
- 0.86
- EV/EBITDA
- 3.15
- Div Yield
- 6.44%
Profitability
- Gross Margin
- 41.74%
- Op Margin
- 17.21%
- Net Margin
- 15.79%
- ROE
- 12.65%
- ROIC
- 8.15%
Growth & Income
- Revenue
- $12.87B · -6.46%
- Net Income
- $2.03B · -23.60%
- EPS
- $1.05 · -28.08%
- Op Income
- $2.21B
- FCF YoY
- -35.63%
Performance & Tape
- 52W High
- $2.28
- 52W Low
- $1.18
- 50D MA
- $1.35
- 200D MA
- $1.75
- Beta
- 0.34
- Avg Volume
- 255
Get TickerSpark's AI analysis on ULIHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ULIHF Coverage
We haven't published any research on ULIHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ULIHF Report →